September 29, 2020
Synklino ApS, an emerging biotech company developing first-in-class breakthrough treatment to eliminate cytomegalovirus (CMV) infections in the transplant setting, today announces the successful closing of a seed financing led by Eir Ventures and Vaekstfonden.
Synklino ApS is a spinout from the University of Copenhagen and the Technical University of Denmark established to develop groundbreaking therapies against devastating viral infections. Synklino is incubated at the BioInnovation Institute in its prestigious Creation House program.
CMV is a virus that infects most people in adulthood and is the main agent involved in infectious complications following transplantation with major risk for morbidity, transplantation complications and increased hospital readmissions. Synklino’s drug candidate SYN002 has the unique potential to eliminate CMV from infected patients by targeting both lytic and latent infection.
Thomas Kledal, co-founder and CEO said: “Our goal is to provide patients a chance to live a full life after receiving a transplant. This financing will enable us to advance our lead program towards clinical testing, strengthen the management team and leverage the highly experienced venture and biotech expertise of Eir Ventures and Vaekstfonden, as we move to the next stage of growth.”
Stephan Christgau, Founding Partner of Eir Ventures, commented: “Synklino has developed a novel, first in class anti-viral therapy with the potential to be a game-changer offering the potential for CMV infection management. No other marketed or pipeline therapy has the potential to eliminate CMV infections in transplant patients. Synklino is a great example of Eir Venture’s strategy to back entrepreneurs in the Nordics developing highly innovative treatments for patients with underserved medical needs.”
Lene Gerlach, Investment Manager, Vaekstfonden, stated: “Vaekstfonden strongly supports spinout companies from Danish universities. Synklino is based on outstanding research performed by high-caliber researchers at the University of Copenhagen and the Danish Technical University. We see great potential in Synklino and its anti-viral drug candidate, which may revolutionize patient therapy and achieve higher standards of good health and well-being.”
John Haurum, Chairman of the Board, concluded: “Synklino’s technology is first-in-class and represents the new generation of anti-infectives that have the potential to make a significant impact in improving transplant patient care, an enormous poorly met medical need. I am looking forward to working with Thomas Kledal, CEO, who brings extensive drug development experience, which combined with the Company’s scientific foundations could lead to products that materially improve the options available to transplantation and infectious disease specialists and their patients.”
